62nd ASH Annual Meeting and Exposition: 802. Chemical Biology and Experimental Therapeutics: Poster III

Oral and Poster Abstracts
Poster

AML, apoptosis, Biological, CML, Diseases, Non-Biological, Mantle Cell Lymphoma, Therapies, chemotherapy, Non-Hodgkin Lymphoma, Biological Processes, enzyme inhibitors, Hemoglobinopathies, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, integrative -omics, metabolomics, pathways

3374

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Tea Pemovska, PhD^1,2^*, Johannes Bigenzahn, MD, PhD^1,3^*, Ismet Srndic, MSc¹^*, Alexander Lercher, MSc¹^*, Andreas Bergthaler, PhD¹^*, Adrian Cesar Razquin, PhD¹^*, Felix Kartnig, MD¹^*, Philipp B. Staber, MD, PhD² and Giulio Superti Furga, PhD^1,4^*

¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
²Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
³Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
⁴Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria

3375

Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells

Kyung Hee Chang, PhD¹^*, Zoe Alaniz¹^*, Yuki Nishida, MD, PhD², Cedric E. Dos Santos, PhD³, Eric Slosberg, PhD⁴^*, Naval Daver, MD⁵ and Michael Andreeff, MD, PhD¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
³Daiichi Sankyo, Inc., Basking Ridge, NJ
⁴Daiichi Sankyo, Inc., Basking Ridgen, NJ
⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3376

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, PhD.¹^*, Jeejin Im¹^*, June H-J H-J Han¹^*, Kyu-Tae Kim, PhD.¹^*, Jeong-Hyeok Yoon, PhD.¹^*, Hanna Cho, PhD.²^*, Seung-Hye Choi, PhD.²^*, David Young, MD.³^*, Bao Nguyen⁴^*, Ruiqi Zhu, PhD.⁵^*, Li Li, MD., PhD.⁴^*, Donald Small, MD., PhD.⁵ and Taebo Sim, PhD.²^*

¹Pharos I&BT Co., Ltd., Anyang, Korea, Republic of (South)
²Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
³Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD
⁴Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
⁵Pediatric Oncology, Johns Hopkins University, Baltimore, MD

3377

Targeting Transcription Checkpoint Using a Novel CDK9 Inhibitor in Mantle Cell Lymphoma

Junwei Lian, PhD¹^*, Yu Xue, PhD²^*, Alexa A Jordan, BS¹^*, Joseph McIntosh, BS¹^*, Yang Liu, PhD¹^*, Michael Wang, MD^1,3, Jia Zhou, PhD²^* and Vivian Changying Jiang, PhD¹

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

3378

Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer

Dhanalakshmi S¹^*, Sridharan Rajagopal, PhD¹^*, Naveen Sadhu²^*, Chandru G¹^*, Amir Siddiqui³^*, Saif Wahid³^*, Basava Prabhu³^*, Neha KS³^*, Sreekala Nair³^*, Rudresh G³^*, Prasanthi Daram³^*, Mohd Zainuddin³^*, Subramanyam J Tantry³^*, Dinesh Thiagaraj³^*, Krishnakumar V³^* and Santosh Vishwakarma³^*

¹Jubilant Therapeutics Inc, Bedminster, NJ
²Jubilant therapeutics Inc, Bedminster, NJ
³Jubilant Biosys Ltd, Bangalore, India

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH